The Filing Desk

Akebia Therapeutics vs Puma Biotechnology

Akebia Therapeutics AKBA · Puma Biotechnology PBYI · Pharmaceuticals

Akebia Therapeutics reported revenue of $236 million in fiscal 2025, about the same as Puma Biotechnology's $228 million in fiscal 2025. Akebia Therapeutics' revenue grew 47.5% in its latest year, and Puma Biotechnology's fell 0.9%. Akebia Therapeutics had an operating margin of 9.9%, against 16.3% at Puma Biotechnology. Free cash flow was $68 million at Akebia Therapeutics and $42 million at Puma Biotechnology.

Side by side

Akebia TherapeuticsPuma Biotechnology
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$236M$228M
Revenue growth47.5%−0.9%
Revenue growth a year, last 5 years−4.3%0.3%
Gross margin83.3%74.5%
Operating margin9.9%16.3%
Net margin−2.3%13.6%
Free cash flow$68M$42M
Free cash flow margin28.7%18.3%
Return on capital—48.2%
Net debt to EBITDA−5.5x−1.4x
Dividends and buybacks$0M$0M
Change in diluted share count21.9%3.2%
Last close$0.42$7.12
P/E at the last close—15.5×
Insider trades, last 12 monthsbought $86,588, sold $962,955sold $2.0 million
Piotroski F-score7 of 98 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Akebia TherapeuticsPuma Biotechnology
Operating margin
Percent of revenue
Akebia TherapeuticsPuma Biotechnology
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Akebia TherapeuticsPuma Biotechnology

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Akebia Therapeutics and Puma Biotechnology pages.